Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by Alzheimer’s, Parkinson’s, and other diseases caused by protei
Employees: 11-50
Total raised: $47M
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | Merieux De... | merieux-pa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.09.2016 | Series E | $47M | - |
Mentions in press and media 4
| Date | Title | Description |
| 09.09.2016 | Proclara Biosciences Secures $47M in Series E Financing | Proclara Biosciences, a Cambridge, MA-based biotechnology company developing novel therapies for diseases caused by protein misfolding, secured $47m in Series E financing. The round was led by existing investors including private investors ... |
| 07.09.2016 | Proclara gets $47M to target protein misfolding in Alzheimer’s and beyond | NeuroPhage Pharmaceuticals hopes to reinvent itself a bit with a new name, Proclara Biosciences, and a cash infusion of $47 million. The Series E financing brings the total raised by the company to more than $110 million. The Cambridge, MA-... |
| 07.09.2016 | Proclara Biosciences Lands $47M Series E | CAMBRIDGE, MA, Biotechnology company developing novel therapies for diseases caused by protein misfolding, has secured $47 million in a Series E financing. >> Click here for more funding data on Proclara Biosciences >> To ex... |
| 07.09.2016 | Proclara Biosciences Raises $47 Million Series E | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that the company has secured $47 million in a Series E financing to suppo... |